The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

This is to notify you that Fresenius Kabi USA, LLC ("Fresenius Kabi") is recalling the below-mentioned lot of Tyenne® (tocilizumab-aazg) Injection, 400 mg/ 20 mL (20 mg/ mL) 20 mL vial.

This recall is being performed to the user level. Fresenius Kabi has decided to take this action due to the presence of glass particles. The investigation reveals this issue is limited to this lot.

The administration of an injectable product containing glass particulates may cause local irritation, pain, or swelling at the infusion site, as well as inflammation of the veins. More seriously, glass particles can cause blockage and clotting in blood vessels, which can cut off blood flow to vital organs, lead to a life-threatening blood clot in the lungs (pulmonary embolism) and cause pe1manent organ damage or death. No adverse event reports have been received for the below-listed lot to date.

PRODUCT: Tyenne® (tocilizumab-aazg) Injection, 400 m2g /20 mL (20 mg /mL) 20 mL vial

NDC NUMBER: 65219-594-20

LOT NUMBER: 16UI07

EXPIRATION DATE: 08/2028

DISTRIBUTION DATES: 03/03/2026 - 03/25/2026